NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Anupam Rasayan Promoter Declares No Encumbrance on 31.80% Stake for FY26
Kiran Pallavi Investments LLC, a key promoter of Anupam Rasayan India Limited, has submitted its annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The promoter entity holds 3,62,06,896 equity shares, which constitutes 31.80% of the company's total equity capital. The filing confirms that no direct or indirect encumbrances or pledges were created on these shares during the reporting period. This disclosure provides assurance regarding the stability of the promoter's shareholding.
முக்கிய அம்சங்கள்
Promoter Kiran Pallavi Investments LLC holds a significant 31.80% stake in the company.Declaration confirms zero shares were pledged or encumbered during the financial year 2025-26.The filing involves 3,62,06,896 equity shares held by the promoter entity.Compliance submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 கவனிக்க வேண்டியவை
Investors can take comfort in the fact that a major portion of the promoter holding remains unencumbered, indicating no immediate debt-related stress at the promoter level. Maintain a watch on overall promoter holding trends in upcoming quarterly reports.
CRISIL Places Anupam Rasayan on 'Rating Watch' Following Bliss GVS Pharma Acquisition Plan
CRISIL has placed Anupam Rasayan's 'CRISIL A+' long-term and 'CRISIL A1' short-term ratings on 'Rating Watch with Developing Implications'. This action follows the company's plan to acquire a 43.3-48.2% stake in Bliss GVS Pharma, which involves a debt component of Rs 300 crore. While FY26 revenue grew to Rs 2,365 crore from Rs 1,439 crore, operating margins compressed to 22.19% from 27.67%. The company has shown significant improvement in its working capital cycle, with inventory days reducing from 510 to 324 days.
முக்கிய அம்சங்கள்
CRISIL A+ rating assigned to new Rs 160 crore NCDs and placed on Watch Developing.Total bank loan facilities enhanced to Rs 1,620 crore from Rs 1,369.82 crore.FY26 revenue increased to Rs 2,365 crore, though margins fell to 22.19% due to limited cost pass-through.Inventory days improved to 324 days (vs 510 days) and receivables to 148 days (vs 190 days).Acquisition of Bliss GVS Pharma stake to be funded via Rs 300 crore debt and balance through equity.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final funding mix of the Bliss GVS acquisition and its impact on the company's leverage. While the improvement in working capital is positive, the compression in operating margins warrants caution regarding cost management.
Anupam Rasayan delivered a landmark FY26 with consolidated revenue growing 65% Y-o-Y to ₹2,384 crores and PAT increasing to ₹222 crores. The company successfully diversified its revenue mix, reducing agrochemical dependence from 76% to 55% while scaling Pharma and Performance Materials. A significant strategic acquisition of Bliss GVS Pharma (43.3% to 48.2% stake) was announced to create an integrated pharmaceutical platform. Management reported strong operating cash flows of ₹334 crores and the completion of its major capex cycle, signaling a shift toward higher asset utilization.
முக்கிய அம்சங்கள்
FY26 consolidated revenue reached ₹2,384 crores, up 65% Y-o-Y, with an EBITDA margin of 23%.Pharma segment revenue grew 15-fold from ₹21 crores in FY22 to ₹339 crores in FY26.Announced acquisition of 43.3% to 48.2% stake in Bliss GVS Pharma to expand into formulations and CDMO.Operating cash flow improved significantly to ₹334 crores due to better working capital management.Jayhawk Fine Chemicals acquisition completed with pro forma annual revenue of approximately $76 million.
👀 கவனிக்க வேண்டியவை
Investors should view the aggressive diversification into Pharma and the completion of the capex cycle as long-term value drivers. Monitor the integration of Bliss GVS and Jayhawk for synergy benefits and margin expansion in FY27.
Anupam Rasayan Allots ₹160 Crore NCDs to Aditya Birla Capital at 10.25% Interest
Anupam Rasayan India Limited has successfully allotted 16,000 secured, unlisted Non-Convertible Debentures (NCDs) worth ₹160 crore to Aditya Birla Capital. The debt carries a coupon rate of 10.25% p.a. and has a short tenure of 13 months, maturing in June 2027. A significant partial redemption of ₹99,500 per NCD is scheduled for September 2026, effectively making it a very short-term bridge loan. The funds are intended for debt repayment, group investments, and general corporate purposes.
முக்கிய அம்சங்கள்
Allotment of 16,000 NCDs with a face value of ₹1,00,000 each, totaling ₹160 crore.Fixed coupon rate of 10.25% p.a. with interest and partial principal payable by September 2026.Secured by a first-ranking pledge over 31,50,000 shares held by Promoter Mr. Anand Sureshbhai Desai.Proceeds to be utilized for repayment of existing debt facilities and investment in group companies.The instrument is unlisted and was issued on a private placement basis to Aditya Birla Capital Limited.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's interest coverage ratio given the 10.25% cost of debt and the increase in promoter share pledging. The structured early redemption suggests this is a temporary liquidity arrangement rather than long-term leverage.
Anupam Rasayan FY26 Revenue Jumps 65% to ₹23,836 Mn; Annual PAT Up 39%
Anupam Rasayan reported a landmark FY26 with consolidated revenue growing 65% YoY to ₹23,836 Mn, driven by the Jayhawk acquisition and new product launches. While annual PAT rose 39% to ₹2,222 Mn, Q4 performance saw a slight dip in margins with PAT falling 11% YoY to ₹560 Mn. The company achieved its highest-ever operating cash flow of ₹3,343 Mn and is expanding its pharma presence through a stake acquisition in Bliss GVS Pharma. The integration of Jayhawk and focus on high-value chemistries like Performance Materials remain key growth drivers.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue increased by 65% YoY to ₹23,836 Mn, while EBITDA grew 32% to ₹5,430 Mn.Annual Profit After Tax (PAT) reached ₹2,222 Mn, representing a 39% growth compared to the previous financial year.Successfully completed the acquisition of US-based Jayhawk Fine Chemicals and signed an agreement for Bliss GVS Pharma.Achieved highest-ever operating cash flow of ₹3,343 Mn, reflecting improved operational efficiency and business scale.Revenue mix diversified with Agrochemicals at 55%, Pharma at 20%, and Performance Materials at 18%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful integration of Jayhawk and the upcoming Bliss GVS acquisition as they pivot the company toward higher-margin segments. While Q4 margins were slightly pressured, the strong annual cash flow and robust product pipeline support a long-term growth thesis in the CDMO space.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Anupam Rasayan to Acquire 43.3-48.2% Stake in Bliss GVS Pharma; Open Offer Announced
Anupam Rasayan India Limited has entered into a definitive agreement to acquire a 43.3% to 48.2% equity stake in Bliss GVS Pharma Limited, alongside an open offer to public shareholders. The acquisition is being financed through a Rs 300 crore term loan and non-controlling non-voting equity instruments. This strategic move aims to create an integrated life sciences platform, combining Anupam's specialty chemical expertise with Bliss GVS's finished dosage formulation capabilities. Bliss GVS brings a portfolio of over 150 branded formulations and US FDA/EU-GMP approved manufacturing facilities.
முக்கிய அம்சங்கள்
Acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma plus a mandatory Open OfferFinancing structured via Rs 300 crore term loan and non-voting equity instrumentsBliss GVS is a global leader in suppositories and pessaries with 150+ branded formulationsStrategic vertical integration from Key Starting Materials (KSMs) to finished dosage formsAccess to US FDA, WHO-GMP, and EU-GMP certified manufacturing facilities in Maharashtra and Daman
👀 கவனிக்க வேண்டியவை
This is a major strategic expansion for Anupam Rasayan into the pharmaceutical formulation space; investors should monitor the acquisition valuation and the progress of the open offer. The integration is expected to unlock synergies in regulated markets like Europe and the US.
Anupam Rasayan to Acquire 74.2% Stake in Bliss GVS Pharma; Recommends ₹1.5 Dividend
Anupam Rasayan has announced a major strategic move to acquire up to 74.20% stake and control of Bliss GVS Pharma Limited, a listed entity. To support its capital requirements, the board has also approved a fundraise of ₹160 crore through the issuance of secured Non-Convertible Debentures (NCDs). Additionally, the company recommended a final dividend of ₹1.5 per share for FY26. While the Deputy CFO has resigned, the company reported audited financial results with an unmodified auditor opinion.
முக்கிய அம்சங்கள்
Proposed acquisition of up to 74.20% equity stake and control of Bliss GVS Pharma Limited.Recommended a final dividend of ₹1.5 per equity share (15% of face value) for FY 2025-26.Approved raising ₹160 crore through private placement of 16,000 secured, rated, unlisted NCDs.Resignation of Mr. Vishal Thakkar from the position of Deputy CFO and Key Managerial Personnel.Audited financial results for FY26 approved with an unmodified audit opinion from statutory auditors.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the valuation and synergy potential of the Bliss GVS Pharma acquisition, as it is a significant expansion. The fundraise via NCDs indicates capital intensity, so checking the impact on the company's leverage is advised.
Anupam Rasayan Deputy CFO Vishal Thakkar Resigns with Immediate Effect
Anupam Rasayan India Limited has announced the resignation of Mr. Vishal Thakkar from his role as Deputy Chief Financial Officer and Key Managerial Personnel, effective May 23, 2026. Mr. Thakkar, who served the company for four years, was notably involved in the firm's M&A activities during his tenure. He is stepping down to explore other opportunities within the group and to focus on his own company. The resignation was processed during a board meeting that concluded at 4:55 p.m. IST on the same day.
முக்கிய அம்சங்கள்
Resignation of Mr. Vishal Thakkar as Deputy CFO and KMP effective May 23, 2026Mr. Thakkar completes a 4-year tenure with the companyReason for exit includes exploring other group opportunities and personal business venturesBoard meeting regarding the resignation lasted approximately 4 hours and 10 minutes
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's next steps regarding the appointment of a successor to ensure continuity in financial leadership. The transition appears amicable as the executive remains within the group ecosystem.
Anupam Rasayan Shareholders Approve Security Creation for Subsidiary Credit Facility
Anupam Rasayan shareholders have approved resolutions to provide guarantees and create security interests over the assets of material subsidiaries, Doriath S.a.r.l. and Jayhawk Fine Chemicals Corporation. These measures secure a credit facility for Doriath S.a.r.l. from Altis XII Pte. Ltd. Both resolutions received overwhelming support, with approximately 99.94% of votes cast in favor. This approval facilitates the company's ability to maintain and manage debt for its international operations.
முக்கிய அம்சங்கள்
Approved guarantees for credit facility availed by Doriath S.a.r.l. from Altis XII Pte. Ltd.Authorized security creation over assets of material subsidiaries Doriath S.a.r.l. and Jayhawk Fine Chemicals.Resolution 1 passed with 99.94% majority (83,892,813 votes in favor).Resolution 2 passed with 99.94% majority (83,892,713 votes in favor).The approval covers the facility even if Doriath S.a.r.l. ceases to be a wholly-owned subsidiary.
👀 கவனிக்க வேண்டியவை
Monitor the impact of this credit facility on the company's consolidated balance sheet and interest coverage ratio. The strong shareholder support reflects confidence in the company's expansion and financing strategy.
Anupam Rasayan Shareholders Approve Subsidiary Financing Guarantees with 99.9% Majority
Anupam Rasayan India Limited has announced the successful passage of two key resolutions through a postal ballot with over 99.9% shareholder approval. The first resolution allows the company to provide guarantees for credit facilities of its subsidiary, Doriath S.a.r.l., even if its ownership status changes in the future. The second resolution authorizes the creation of security interests over the assets of Doriath S.a.r.l. and Jayhawk Fine Chemicals Corporation. These approvals provide the company with significant financial flexibility and ensure continued support for its international operations.
முக்கிய அம்சங்கள்
Shareholders approved guarantees for Doriath S.a.r.l. with a 99.94% majority, representing 83.89 million votes in favor.Special resolution for security interests over Jayhawk Fine Chemicals assets passed with 99.94% support.Total voter turnout was approximately 73.74% of the total outstanding shares, with 100% promoter participation in favor.The resolutions facilitate credit facilities for international subsidiaries, ensuring operational liquidity and strategic flexibility.
👀 கவனிக்க வேண்டியவை
Investors should monitor for any potential divestment or strategic partnership involving Doriath S.a.r.l., as these resolutions provide the necessary financial framework for such transitions.
CRISIL has reaffirmed Anupam Rasayan's long-term rating at 'CRISIL A+/Stable' and removed it from 'Rating Watch with Negative Implications'. This resolution follows the successful integration of Tanfac Industries and a demonstrated improvement in the working capital cycle, with inventory days dropping from 270 to 210. The company maintained steady revenue of ₹1,101 crore in 9M FY24 with strong EBITDA margins of 27-28%. The stable outlook reflects the company's established market position and long-term contracts with global agrochemical and fluorochemical players.
முக்கிய அம்சங்கள்
CRISIL reaffirmed Long-Term rating at 'A+/Stable' and Short-Term at 'A1' for ₹1369.82 crore bank facilities.Removed 'Rating Watch with Negative Implications' following the successful acquisition and integration of Tanfac Industries.Inventory days significantly improved to 210 days from 270 days, easing working capital pressure.Reported 9M FY24 revenue of ₹1,101 crore with healthy operating margins sustained at 27-28%.Net debt to EBITDA ratio is expected to remain manageable between 2.5x to 3.0x in the medium term.
👀 கவனிக்க வேண்டியவை
The removal of the negative watch indicates reduced financial risk and successful deleveraging post-acquisition. Investors should view this as a sign of operational stability, though they should continue to monitor the working capital cycle and global demand for specialty chemicals.
Anupam Rasayan Completes $150 Million Acquisition of US-based Jayhawk Fine Chemicals
Anupam Rasayan has successfully completed the 100% acquisition of Jayhawk Fine Chemicals Corporation for approximately $150 million. The acquisition is financed through $129 million from Oaktree affiliate Altis XII and $21 million from Axis Bank, making it EPS accretive upon consolidation. Jayhawk, a US-based specialty chemical firm, provides high-performance materials to sectors like semiconductors and aerospace, with 65% of its revenue coming from these high-growth areas. This move significantly expands Anupam's global footprint and integrates its operations with Tanfac Industries for enhanced synergies.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake in Jayhawk Fine Chemicals for a total consideration of ~$150 million.Financing structure includes $129 million from Oaktree affiliate and $21 million debt from Axis Bank.Jayhawk generates ~65% of revenue from performance materials serving electronics, energy, and aerospace sectors.The transaction is expected to be immediately EPS accretive and will be fully consolidated with Anupam Rasayan.Strategic expansion into the U.S. market to manufacture key N-1 molecules for critical high-tech sectors.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this acquisition as it diversifies revenue streams into high-margin US tech sectors and is EPS accretive. Monitor the integration with Tanfac Industries and the impact on operating margins in the coming quarters.
Anupam Rasayan Secures USD 30 Million ECB Facility for Monitchem Kansas Acquisition
Anupam Rasayan has executed a facility agreement to raise USD 30 million through External Commercial Borrowing (ECB) from Axis Bank and other syndicated lenders. The proceeds are specifically earmarked to partially finance the acquisition of Monitchem Kansas S.à r.l. and associated costs. The loan is secured by a pari passu charge on the company's movable and immovable fixed assets and is effective from February 19, 2026. This financing follows recent regulatory amendments by the RBI regarding foreign exchange management.
முக்கிய அம்சங்கள்
Secured a USD 30 million (approx. ₹250 Cr) ECB facility from Axis Bank IBU GIFT City and syndicated lenders.Funds will be utilized for the acquisition of Monitchem Kansas S.à r.l. and associated intragroup loan receivables.Loan is secured by first ranking pari passu charge on movable fixed assets and identified immovable properties.The facility became effective on February 19, 2026, following compliance with RBI's 2026 Foreign Exchange Management amendments.Company corrected previous disclosure dates for the Share Subscription Agreement to February 14, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward completing a strategic acquisition, though they should monitor the company's debt-to-equity ratio post-drawdown. Watch for further updates on the completion of the Monitchem Kansas acquisition and its expected contribution to earnings.
Anupam Rasayan Q3 FY26 PAT Up 12% to ₹61 Cr; 9M Revenue Surges 84% to ₹1,730 Cr
Anupam Rasayan reported a robust 84% YoY growth in 9M FY26 revenue reaching ₹1,730 crores, driven by the scale-up of commercial molecules and improved capacity utilization. The company's PAT for the nine-month period rose 71% to ₹166 crores, while Q3 FY26 PAT grew 12% YoY to ₹61 crores. A significant strategic move was the announcement of the 100% acquisition of US-based Jayhawk Fine Chemicals, which is expected to be EPS accretive immediately upon closing. Segmental performance was strong, with the Performance Material vertical growing 245% YoY and Pharma growing 85% YoY during the first nine months.
முக்கிய அம்சங்கள்
9M FY26 consolidated revenue grew 84% YoY to ₹1,730 crores with EBITDA margins at 23%.Performance Material segment revenue surged 245% YoY in 9M FY26, contributing 17% to total sales.Pharma segment delivered 85% YoY growth in 9M FY26, now representing 19% of the revenue mix.Signed definitive agreement to acquire 100% of Jayhawk Fine Chemicals (USA) to establish a direct manufacturing presence in North America.LOIs and contracts contributed over ₹250 crores to the revenue during the nine-month period.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of the Jayhawk acquisition and the continued ramp-up of the high-growth Performance Material and Pharma segments. The company's successful backward integration through Tanfac and expansion into the US market strengthens its long-term competitive position.
Anupam Rasayan Executes $150M Corporate Guarantee and $30M ECB for Global Acquisition
Anupam Rasayan India Limited has finalized a series of financial agreements to fund its overseas acquisition of Monitchem Kansas S.à r.l. through its subsidiary Doriath. The company has executed corporate guarantees totaling USD 150 million and secured a USD 30 million External Commercial Borrowing (ECB) from Axis Bank. To back these facilities, the company has pledged its 100% stake in Doriath and entered a non-disposal undertaking for its 25.80% stake in Tanfac Industries Limited. This structured financing facilitates the strategic acquisition while significantly increasing the company's contingent liabilities and asset encumbrance.
முக்கிய அம்சங்கள்
Executed corporate guarantees aggregating to USD 150 million to support credit facilities for overseas subsidiaries.Secured a USD 30 million External Commercial Borrowing (ECB) from Axis Bank for the parent company.Wholly-owned subsidiary Doriath availed a USD 20 million credit facility from Altis XII Pte. Ltd. for acquisition purposes.Provided a non-disposal undertaking for the company's 25.80% shareholding in Tanfac Industries Limited as security.Acquisition involves 100% of Monitchem Kansas S.à r.l. and associated intragroup loan receivables.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue and margin contribution from the newly acquired Monitchem Kansas to ensure it offsets the increased debt servicing costs. The significant encumbrance of assets and the Tanfac stake undertaking are key risk factors to watch in the consolidated balance sheet.
Anupam Rasayan Secures $50M Financing and $150M Guarantees for Monitchem Kansas Acquisition
Anupam Rasayan has executed definitive agreements to fund the acquisition of Monitchem Kansas S.à r.l. through its subsidiary Doriath. The financing structure includes a $30 million External Commercial Borrowing (ECB) for the parent company and a $20 million credit facility for Doriath. Additionally, Batam S.à r.l. will invest $110 million into Doriath to facilitate the transaction. To secure these facilities, Anupam Rasayan has provided corporate guarantees totaling $150 million and a non-disposal undertaking for its 25.8% stake in Tanfac Industries.
முக்கிய அம்சங்கள்
Secured $30 million ECB from Axis Bank and $20 million credit facility for subsidiary Doriath.Batam S.à r.l. to invest $110 million into Doriath to fund the 100% acquisition of Monitchem Kansas.Company provided corporate guarantees aggregating to $150 million to secure the credit facilities.Security includes a non-disposal undertaking of the company's 25.8% shareholding in Tanfac Industries Limited.Acquisition of 100% stake in Doriath and 15% stake in Batam completed/in-process to facilitate the deal.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major strategic expansion, though they should monitor the impact of the $150 million guarantee and increased debt on the balance sheet. The integration of Monitchem Kansas will be the key driver for future earnings growth.
Anupam Rasayan Q3 Revenue Up 31%; Announces $150M Acquisition of US-based Jayhawk Fine Chemicals
Anupam Rasayan reported a robust 9M FY26 performance with consolidated revenue growing 84% YoY to ₹17,297 million and PAT increasing 71% to ₹1,662 million. A major strategic highlight is the definitive agreement to acquire US-based Jayhawk Fine Chemicals for an enterprise value of $134 million, which is expected to significantly enhance its global footprint and performance materials portfolio. While Q3 FY26 revenue grew 31% YoY to ₹5,124 million, consolidated EBITDA margins compressed to 25% from 31% in the year-ago period. The acquisition will be funded through a mix of internal accruals, debt, and quasi-equity, creating a pro-forma entity with approximately $243 million in revenue.
முக்கிய அம்சங்கள்
9M FY26 consolidated revenue surged 84% YoY to ₹17,297 Mn, with PAT rising 71% to ₹1,662 Mn.Q3 FY26 standalone PAT witnessed a 150% YoY increase to ₹479 Mn on the back of 89% standalone revenue growth.Acquisition of Jayhawk Fine Chemicals (USA) for a total consideration of ~$150M, adding ~$78M in annual revenue.Consolidated EBITDA for 9M FY26 stood at ₹4,024 Mn, representing a 53% YoY growth despite margin pressure.Life Science related specialty chemicals continue to dominate the business mix, contributing 83% of total revenues.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strategic benefits of the Jayhawk acquisition which provides direct access to North American innovators and high-value performance materials. While the growth momentum is strong, monitoring the stabilization of EBITDA margins and the successful integration of the US acquisition will be key for long-term value.
Anupam Rasayan Q3FY26 Revenue Jumps 33% to ₹5,145 Mn; Announces US Acquisition
Anupam Rasayan reported a robust 33% YoY increase in revenue for Q3FY26, reaching ₹5,145 million. Profit After Tax (PAT) grew by 12% YoY to ₹606 million, while EBITDA margins stood at 25.20%. A significant strategic development is the definitive agreement to acquire Jayhawk Fine Chemicals in the USA, aimed at strengthening their presence in North American regulated markets. The company continues to show strong momentum in its custom synthesis and specialty chemicals business with 9M FY26 revenue reaching ₹17,297 million.
முக்கிய அம்சங்கள்
Total Revenue for Q3FY26 grew 33% YoY to ₹5,145 million compared to ₹3,866 million in Q3FY25.EBITDA increased by 7% YoY to ₹1,296 million with an EBITDA margin of 25.20%.Profit After Tax (PAT) rose 12% YoY to ₹606 million from ₹542 million in the previous year.9M FY26 consolidated revenue reached ₹17,297 million with EBITDA of ₹4,024 million.Signed definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States.
👀 கவனிக்க வேண்டியவை
The strong top-line growth and strategic US acquisition signal positive long-term expansion; however, investors should monitor EBITDA margin trends which grew slower than revenue. Hold for long-term gains as the company integrates the Jayhawk acquisition into its global platform.
Anupam Rasayan Q3 Standalone PAT Jumps 150% YoY to ₹47.9 Cr; Revenue Up 89% YoY
Anupam Rasayan reported a strong year-on-year performance for Q3 FY26, with standalone revenue from operations rising 89% to ₹401.37 crore compared to ₹212.09 crore in the same quarter last year. Standalone Profit After Tax (PAT) surged by 150% YoY to ₹47.92 crore, although revenue saw a sequential decline from Q2 FY26. The company successfully utilized ₹277.5 crore from a preferential allotment for debt repayment and general corporate purposes. For the nine-month period, the company's performance shows a massive recovery with PAT reaching ₹119.01 crore compared to ₹34.58 crore in the previous year.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations grew 89.2% YoY to ₹4,013.67 million in Q3 FY26.Standalone Net Profit (PAT) increased by 150.4% YoY to ₹479.19 million.9M FY26 Standalone PAT stands at ₹1,190.13 million, a 244% increase over 9M FY25.Finance costs for 9M FY26 rose to ₹1,020.65 million from ₹776.81 million YoY.Successfully raised and utilized ₹2,775 million via preferential allotment for debt reduction by December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant year-on-year recovery and the positive impact of debt reduction on the balance sheet. Monitor the sequential revenue volatility and the performance of the Tanfac Industries associate for consolidated growth trends.
Anupam Rasayan Denies Rumors of Stake Acquisition in Bliss GVS Pharma
Anupam Rasayan India Limited has officially clarified media reports regarding a rumored stake acquisition in Bliss GVS Pharma Ltd. The company stated that no such material event or information exists that requires disclosure under SEBI Regulation 30. Management has chosen not to comment further on the speculation while emphasizing their ongoing compliance with disclosure norms. This clarification was issued on February 13, 2026, to address market rumors and prevent misinformation.
முக்கிய அம்சங்கள்
Official denial of media reports regarding a potential stake purchase in Bliss GVS Pharma.Clarification provided under SEBI (LODR) Regulation 30(11) on February 13, 2026.Company maintains there is no undisclosed material information at this time.Management refuses to comment on further market speculation appearing in electronic media.
👀 கவனிக்க வேண்டியவை
Investors should treat the acquisition reports as unverified speculation and avoid making trading decisions based on these rumors. Monitor official company filings for any actual strategic developments or future M&A activity.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
